ASCO Annual Meeting: Gynecologic Cancer

Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.

An expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.

Results reported at the 2021 ASCO Annual Meeting show that half of patients treated in the FORWARD II trial achieved a response to therapy with mirvetuximab soravtansine and bevacizumab.

Patients with platinum-sensitive recurrent ovarian cancer treated with niraparib had an acceptable safety profile regardless of the dose being adjusted for weight.

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.

Data presented at the 2021 ASCO Annual Meeting on 3 prominent trials of niraparib as maintenance for ovarian cancer after a positive response to platinum-based chemotherapy further support the use of the agent in multiple settings.

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

The US Oncology expert reported that secondary surgical cytoreduction may not lead to improved outcomes in women platinum-sensitive, recurrent ovarian cancer.

The MSK expert discussed how pre- and post-genetic testing online education made patients more knowledgeable about genetic testing.

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.

The expert discussed study methods from the NRG Oncology/Gynecologic Oncology Group (GOG) study presented at the 2020 ASCO Virtual Program.

At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

The expert discussed study methods and results from the MAGENTA trial evaluating pre and/or post-test genetic counseling.

The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

The study results indicated that pembrolizumab monotherapy was associated with modest antitumor activity in patients with recurrent advanced ovarian cancer.

The Dana-Farber Cancer Institute expert discussed pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

The MSK expert discussed the need for targeted testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.

The MD Anderson Cancer Center expert spoke about the disconnect in women who are at risk for ovarian cancer to actually receive genetic counseling.

A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status.

Treatment with olaparib in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

An analysis of the phase III SOLO1 trial examined safety signals with olaparib maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation.

A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.

Researchers analyzed recurrence and survival outcomes for clear cell ovarian carcinoma in the JGOG3017/GCIG trial.

Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy.

This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.

Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.